Enovis (NYSE:ENOV) Director Sharon Wienbar Acquires 874 Shares of Stock

Enovis Corporation (NYSE:ENOV) Director Sharon Wienbar acquired 874 shares of the business’s stock in a transaction that occurred on Tuesday, November 10th. The stock was purchased at an average cost of $28.43 per share, with a total value of $24,847.82. Following the acquisition, the director directly owned 44,651 shares of the company’s stock, valued at $1,269,427.93. This trade represents a 2.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

Enovis Stock Down 3.2%

ENOV stock opened at $27.63 on Friday. Enovis Corporation has a fifty-two week low of $16.70 and a fifty-two week high of $31.81. The business’s 50-day moving average is $20.36 and its two-hundred day moving average is $23.19. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.08 and a current ratio of 2.15. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -3.00 and a beta of 1.31.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.11. Enovis had a positive return on equity of 13.23% and a negative net margin of 22.86%. The business had revenue of $558.73 million during the quarter, compared to the consensus estimate of $557.12 million. During the same period in the previous year, the company posted $0.75 EPS. The business’s quarterly revenue was up 1.8% compared to the same quarter last year. As a group, analysts forecast that Enovis Corporation will post 3.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ENOV. Paradigm Capital Management Inc. NY purchased a new position in shares of Enovis during the 2nd quarter valued at about $28,533,000. Bank of America Corp DE bought a new position in shares of Enovis during the 2nd quarter valued at approximately $11,502,000. Private Management Group Inc. increased its holdings in Enovis by 31.3% in the 3rd quarter. Private Management Group Inc. now owns 1,792,429 shares of the company’s stock worth $32,748,000 after acquiring an additional 427,347 shares in the last quarter. Man Group plc purchased a new stake in Enovis in the 2nd quarter worth approximately $8,711,000. Finally, Front Street Capital Management Inc. raised its stake in Enovis by 106.1% during the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock worth $16,973,000 after acquiring an additional 384,124 shares during the period. Institutional investors own 98.45% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on ENOV shares. UBS Group restated a “buy” rating and set a $44.00 target price on shares of Enovis in a research report on Monday, October 5th. Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Zacks Research upgraded shares of Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Weiss Ratings upgraded shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, November 2nd. Finally, BMO Capital Markets set a $27.00 price objective on shares of Enovis in a research report on Tuesday, September 1st. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Enovis has a consensus rating of “Moderate Buy” and a consensus target price of $38.62.

Key Enovis News

Here’s some of the latest news about ENOV:

• Positive Sentiment: Directors Angela S. Lalor and Sharon L. Wienbar reported purchases on November 10 and 11, totaling 3,531 shares worth about $100,000. The buying may bolster investor confidence, although the transactions are relatively modest and do not guarantee future performance. Lalor SEC filing Wienbar SEC filing
• Neutral Sentiment: Enovis said management will present at the Jefferies Global Healthcare Conference in London on November 17. The announcement provides an opportunity for investors to hear from management but disclosed no new financial guidance or business developments. Conference announcement

About Enovis

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.